Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular assist devices such as the Impella CP, which unloads the left ventricle and improves hemodynamic tolerance during the procedure. 

However, the standard femoral implantation technique requires a 14 F introducer sheath, which is associated with a relevant incidence of vascular and bleeding complications (reported around 13%), particularly in patients with small femoral arteries or peripheral vascular disease. In this context, the authors evaluated the feasibility and safety of an alternative femoral implantation technique known as “sheathless” implantation (without introducer sheath), which avoids the use of the sheath with the hypothesis of reducing these vascular complications.

A total of 18 consecutive patients treated at two Italian centers starting in 2024 were prospectively included. The mean age was 66 years and 78% were men. The mean left ventricular ejection fraction was approximately 33%. Six patients (33%) presented with cardiogenic shock (five in the setting of acute coronary syndrome and one due to mitral valve rupture), while the remaining patients underwent elective high-risk PCI for complex coronary artery disease, including three-vessel disease, left main coronary artery involvement, and multiple chronic total occlusions. The minimum diameter of the common femoral artery ranged between 6 and 7 mm.

Read also: OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes.

The technique consisted of ultrasound-guided puncture of the common femoral artery with initial placement of an 8 F introducer sheath, pre-closure using vascular suture devices, progressive dilation of the access tract, and subsequent direct advancement of the Impella CP catheter over a 0.018” guidewire without using the 14 F introducer sheath.

Study Results: Sheathless Femoral Impella Implantation Achieves 100% Procedural Success with No Vascular Complications at 30 Days

The use of Impella via a sheathless femoral technique was successful in 100% of patients. In all cases, PCI was completed with adequate hemodynamic support and device stability. The mean procedural duration was 144 ± 56 minutes, the average contrast volume was 137 ± 57 mL, and the mean radiation exposure (DAP) was 1528 cGy/cm². Percutaneous closure was performed in all patients, in some immediately after completion of PCI and in others after several hours of support, without requiring surgical repair or endovascular treatment of the vascular access.

Read also: One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER.

Regarding the primary study endpoint, no major or minor vascular complications related to femoral access were recorded during hospitalization or at 30-day follow-up, representing a 0% rate in this initial cohort. Hemostasis was achieved in all cases using suture-based vascular closure devices, either alone or combined with plug-type devices.

Conclusion: The Sheathless Femoral Impella Technique May Reduce Vascular Complications in High-Risk PCI and Cardiogenic Shock

The authors conclude that sheathless femoral implantation of the Impella CP is technically feasible and safe in this initial series of patients undergoing high-risk PCI or presenting with cardiogenic shock. This strategy may reduce the risk of vascular complications associated with the use of the 14 F introducer sheath and may be particularly useful in patients with small femoral arteries or a high bleeding risk. However, this is a small observational series, and larger prospective studies are required to confirm these findings and to define the role of this technique in contemporary interventional practice.

Original Title: Sheathless Femoral Impella Implantation: A Safer Hemodynamic Support in High-Risk PCI and Cardiogenic Shock.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...